Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Conditions:  Leiomyosarcoma;  Myxofibrosarcoma;  Resectable Dedifferentiated Liposarcoma;  Resectable Soft Tissue Sarcoma;  Resectable Undifferentiated Pleomorphic Sarcoma;  Soft Tissue Fibrosarcoma;  Spindle Cell Sarcoma;  Stage I Retroperitoneal Sarcoma American Joint Committee on Cancer (AJCC) v8;  Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;  Stage IA Retroperitoneal Sarcoma AJCC v8;  Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;  Stage IB Retroperitoneal Sarcoma AJCC v8;  Stage IB Soft Tissue Sarcoma of the Tru nk and Extremities AJCC v8;  Stage II Retroperitoneal Sarcoma AJCC v8;  Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;  Storiform-Pleomorphic Malignant Fibrous Histiocytoma;  Synovial Sarcoma;  Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells;  Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant Interventions:  Procedure: Definitive Surgical Resection;  Drug: Immunotherapeutic Agent;  Biological: Nivolumab;  Radiation: Radiation Therapy Sponsors:  Jonsson Comprehensive Cancer Center;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials